<DOC>
	<DOC>NCT02496845</DOC>
	<brief_summary>VL#FIA3-30 is a preparation intended for topical use, applied on the penis, for the treatment of ED.</brief_summary>
	<brief_title>Safety and Clinical Efficacy of Local Topical Treatment for Erectile Dysfunction</brief_title>
	<detailed_description>VasoLead's preparation to treat erectile dysfunction (ED), VL#FIA3-30, is composed of 2 active pharmaceutical ingredients, both act as vasodilators via different mechanisms. Both are currently used orally in the USA and Europe for the treatment of hypertension, angina pectoris and other diseases.</detailed_description>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<criteria>Signed written informed consent. ED for more than six months in duration. IIEFEF domain score at baseline from 11 to 19 . Willingness for a minimum of two sexual attempts during the short period of this study. At least 50% unsuccessful sexual intercourse for 4 attempts on 4 different days. A stable heterosexual relationship with the same partner for more than six months. Age 25 to 75 years old. Neurological pathology; Prior radical prostatectomy; Any unstable medical or psychiatric condition, spinal cord injury, or penile anatomical abnormalities; Clinically significant chronic hematological disease; Cardiovascular conditions that prevent sexual activity (CHF or severe coronary artery disease); History of myocardial infarction, stroke, or lifethreatening arrhythmia within 6 months prior to enrollment into the study; Use of antiandrogens, or oral or injectable androgens; Documented hypotension (BP below 100 systolic or 70 diastolic) or known orthostatic hypotension; Routine use of more than 2 antihypertensive medications; Use of oral nitrates within 3 months prior to enrollment into the study; Cancer within the last 3 years; Documented allergic reaction; Investigators impression for patient noncompliance; Hepatic or renal failure; History of HIV, hepatitis B, hepatitis C; Is an immediate family member of personnel directly affiliated with the study at the investigative site, or is personally directly affiliated with the study at the investigative site; Subject has taken any investigational medication within 30 days prior of entry into the study Employed by VasoLead (2012) Ltd.</criteria>
	<gender>Male</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>